The Prescription Rate of Sglt Inhibitors and Glp1 Receptor Agonists in Patients With Type 2 Dm, According to the Ada and Esc Criteria in Three Diabetes Centers in Iran Publisher



Rs Sajad Raheleh SADAT ; M Baghban MAHBUBE ; M Siavash Dastjerdi MANSOUR
Source: Journal of Isfahan Medical School Published:2025

Abstract

Background: This study aimed to determine the prescription rates of SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) in type 2 diabetes (T2D) patients according to European Society of Cardiology (ESC) and American Diabetes Association (ADA) guidelines at three Iranian diabetes centers. Methods: A cross-sectional analysis was conducted on the medical records of T2D patients (n = 303) from three centers: the Isfahan Endocrine Research Center (n = 129), the Isfahan Social Security Clinic (n = 30), and the Qom Social Security Clinic (n = 144), between 2019 and 2021. Findings: According to ESC and ADA criteria, 84% and 68% of patients were eligible for SGLT2i and GLP-1 RA, respectively. However, only 13.5% received these medications. Key reasons for non-prescription included: high cost, insurance non-coverage due to concurrent insulin pen use (28 patients), injection aversion, and physicians’ unfamiliarity with these drug classes. Conclusion: The overall utilization of SGLT2i and GLP-1 RA among eligible patients remains low. Our findings highlight opportunities to optimize the use of these drugs for preventing future cardiovascular complications, such as periodic training for primary care physicians and expanding insurance coverage to ensure equitable access. © 2025 Elsevier B.V., All rights reserved.